There's a drug that extends lifespan in every organism it's been tested in. Yeast. Worms. Flies. Mice. Every single time. The effect size in mice is between 9% and 26%, depending on the study and the strain. No other compound in longevity science comes close to that track record.

It costs about thirty dollars a month.

And most longevity clinics won't touch it.

What rapamycin actually is

Rapamycin was discovered in the 1970s in soil samples from Easter Island — Rapa Nui, hence the name. It was originally developed as an antifungal, then repurposed as an immunosuppressant for organ transplant patients. The FDA approved it under the brand name Sirolimus in 1999.

But here's where things get interesting. Rapamycin inhibits a protein complex called mTOR (mechanistic target of rapamycin). mTOR is essentially your body's growth-versus-maintenance switch. When mTOR is highly active, your cells prioritize growth, proliferation, protein synthesis. When it's suppressed, cells shift toward autophagy — cellular cleanup, repair, recycling damaged components.

This is the same pathway that caloric restriction activates. The same pathway that fasting activates. Rapamycin just does it pharmacologically, reliably, and with a dose you can measure. (Other compounds hit this same pathway through different mechanisms -- SGLT2 inhibitors do it by dumping glucose, GLP-1 agonists through anti-inflammatory signaling.)

The evidence is not subtle

I'm going to be direct: rapamycin has the most consistent animal longevity data of any drug that exists. Nothing else has extended lifespan in every mammalian model tested.

The landmark study was the NIA's Interventions Testing Program in 2009. They gave rapamycin to genetically heterogeneous mice starting at 600 days old — that's roughly equivalent to a 60-year-old human. Lifespan extension: 14% in females, 9% in males. This was the first time any drug had extended lifespan in mammals when started late in life.

Since then, the data has piled up. A 2023 meta-analysis pooled 47 independent studies on rapamycin and mammalian lifespan. The median effect was a 12% lifespan extension. But the consistency is what matters most. Not a single study showed lifespan shortening. Zero. Out of forty-seven.

Beyond raw lifespan numbers, rapamycin improves cardiac function in aging mice, reverses age-related cardiac hypertrophy, improves immune function in elderly humans (yes, an immunosuppressant that improves immune function — I'll get to that), reduces cancer incidence, and preserves cognitive function. The PEARL trial — the first rapamycin safety RCT in healthy adults — completed in 2025 showing it was well tolerated, with women on 10mg showing improved lean mass and pain scores. The breadth of data across organ systems is remarkable.

The immunosuppression thing

This is where most physicians stop reading and start saying no.

"It's an immunosuppressant. You can't give that to healthy people."

Here's the nuance they're missing. At transplant doses — 2–5 mg daily, continuously — rapamycin absolutely suppresses the immune system. That's the whole point for transplant patients.

But at longevity doses — typically 3–6 mg once weekly — something different happens. A 2014 study by Mannick et al., published in Science Translational Medicine, gave low-dose rapamycin analogs to elderly patients for six weeks. Their immune response to influenza vaccination improved by about 20%. Their immune systems got better, not worse.

The likely explanation: low-dose intermittent rapamycin selectively suppresses senescent immune cells while allowing healthy immune cell proliferation during the drug-free days. You're pruning the dead wood instead of clear-cutting the forest.

This isn't settled science. I want to be honest about that. We don't have 20-year safety data on weekly rapamycin in healthy adults. But the mechanistic rationale is sound, and the early human data is encouraging.

How people actually use it

The most common longevity protocol looks something like this:

Some practitioners cycle it — eight weeks on, four weeks off. Others run it continuously. There's no consensus yet on which approach is best because, frankly, we're early.

The side effects at these doses are generally mild. Mouth sores (aphthous ulcers) are the most common, affecting maybe 15–20% of users. They're annoying but not dangerous and usually resolve with dose adjustment. Some people see lipid changes — LDL and triglycerides can tick up. That's manageable and worth monitoring.

The serious adverse events seen in transplant patients — increased infection risk, impaired wound healing, metabolic dysfunction — occur at much higher doses given daily, not at the once-weekly longevity protocol.

The access problem (and why clinics don't push it)

Rapamycin requires a prescription. Most primary care physicians won't prescribe it off-label for longevity because it's not in any guideline and they don't want the liability. Fair enough. That's a systemic problem, not an individual physician problem.

Longevity clinics could prescribe it. Many of them are happy to prescribe peptides that cost $500 a month with far less evidence. They'll put you on NAD+ IVs at $750 per session. They'll sell you exosome injections for thousands of dollars.

But rapamycin? Generic sirolimus from a compounding pharmacy runs $25–40 per month. There's no markup opportunity. No proprietary protocol. No concierge angle.

I'm not saying every clinic avoids it for financial reasons. Some genuinely have concerns about the immunosuppression angle. But the pattern is hard to ignore: the intervention with the strongest evidence is one of the least frequently recommended by the clinics charging premium prices for longevity programs.

You can access rapamycin through:

  1. A longevity-focused physician who's comfortable with off-label prescribing. They exist. You may need to look.
  2. Telemedicine platforms that specialize in longevity medicine. Several now offer rapamycin protocols.
  3. Compounding pharmacies fill the prescription once you have one. Cost is typically $25–40/month depending on the dose.

Brand-name Sirolimus from a retail pharmacy is more expensive — sometimes $200+ per month. The compounding route is the way most people go.

What we still don't know

I've been pretty bullish here, so let me pump the brakes for a paragraph.

We don't have randomized controlled trial data showing rapamycin extends human lifespan. That trial would take decades and will probably never be run. We don't have long-term safety data in healthy adults using weekly dosing. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) is underway and will help, but results are still years out. We're extrapolating from animal models, short-term human studies, and mechanistic understanding.

That's a real limitation. Anyone who tells you rapamycin is "proven" to extend human lifespan is overstating the evidence.

But anyone who dismisses it is ignoring the most consistent dataset in all of longevity research.

My take

If you're serious about longevity — not the Instagram version, not the biohacker theater of ice baths and red light panels — rapamycin should probably be the first pharmacological intervention you consider. The evidence is stronger than anything else available. The cost is negligible. The risk profile at longevity doses appears manageable.

Is it for everyone? No. People who are immunocompromised, planning surgery, or dealing with active infections should stay away. Anyone considering it should work with a physician who understands the protocol and commits to monitoring.

But the gap between rapamycin's evidence base and its clinical adoption is one of the most striking things in longevity medicine right now. And that gap has more to do with economics and institutional inertia than science.

Free Download

The Longevity Scorecard

Every intervention rated, priced, and summarized on one page.